Ciphergen Expands License Agreement with Genencor for Chromatographic Sorbents for Therapeutic Monoclonal Antibody Production
FREMONT, Calif. - Ciphergen Biosystems, Inc. announced the expansion of its existing License Agreement with Genencor International, Inc. covering the production and marketing of products based on certain of Genencor's proprietary Hydrophobic Charge Induction chromatography technology.
Ciphergen employs this technology in the production of MEP HyperCel(R) by its BioSepra(R) process chromatography division. MEP Hypercel is a high capacity, high selectivity sorbent with a number of significant advantages over Protein A sorbents for the capture, purification and production of monoclonal antibodies.
Under the expanded terms of the agreement, Ciphergen has exclusive, worldwide right to use Genencor's technology for the production of MEP chromatographic sorbents as well as MEP membranes. Furthermore, Ciphergen has the right to both distribute products based on this technology through its own channels and third parties. The agreement also allows Ciphergen to sub-contract MEP Hypercel manufacturing rights under the license to third parties under certain conditions. Financial terms were not disclosed.
Monoclonal antibodies constitute the largest number of protein-based therapeutic and diagnostic molecules currently in clinical trials. Affinity chromatography on Protein A-based sorbents is a very widely used antibody purification method, but is plagued by many known problems including cost, lifetime in usage and leaching issues. The physical properties of MEP HyperCel allow it to be used in production processes at approximately 1/3 of the cost of Protein A-based sorbents, with approximately 2 times the productivity.
"We are extremely pleased by the expansion of this license agreement, which broadens our rights and enhances our ability to promote acceptance of MEP HyperCel by monoclonal antibody manufacturers," stated William E. Rich, President and CEO of Ciphergen. "The price and productivity advantages of MEP HyperCel over Protein A-based products has already resulted in this product being evaluated in over 100 processes and employed in 5 processes for the production of material for clinical trials."
"MEP is a part of our portfolio of bioprocessing technologies that offers tremendous advantages in the purification of monoclonal antibodies," said Gary Hooper, Vice President of Business Development for Genencor International. "Ciphergen is well positioned to create wider market acceptance for use of MEP-based products and services in a rapidly growing field."
Other news from the department business & finance
These products might interest you
Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes
Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates
Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times
Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"
Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures
Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic World Chromatography
Chromatography enables us to separate, identify and thus understand complex substances. Whether in the food industry, pharmaceutical research or environmental analysis - chromatography opens up a treasure trove of information about the composition and quality of our samples. Discover the fascinating world of chromatography!
Topic World Chromatography
Chromatography enables us to separate, identify and thus understand complex substances. Whether in the food industry, pharmaceutical research or environmental analysis - chromatography opens up a treasure trove of information about the composition and quality of our samples. Discover the fascinating world of chromatography!
